Pfizer Inc. (PFE): Price and Financial Metrics


Pfizer Inc. (PFE): $43.94

-0.25 (-0.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PFE POWR Grades


  • PFE scores best on the Growth dimension, with a Growth rank ahead of 93.82% of US stocks.
  • PFE's strongest trending metric is Value; it's been moving up over the last 48 weeks.
  • PFE's current lowest rank is in the Momentum metric (where it is better than 13.9% of US stocks).

PFE Stock Summary

  • With a market capitalization of $247,759,558,452, Pfizer Inc has a greater market value than 99.34% of US stocks.
  • Pfizer Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.65% of US equities in our set.
  • With a year-over-year growth in debt of -38.31%, Pfizer Inc's debt growth rate surpasses just 13.69% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Pfizer Inc, a group of peers worth examining would be LLY, NFLX, CSCO, NVO, and ORCL.
  • Visit PFE's SEC page to see the company's official filings. To visit the company's web site, go to www.pfizer.com.

PFE Valuation Summary

  • PFE's price/sales ratio is 5; this is 55.95% lower than that of the median Healthcare stock.
  • PFE's price/sales ratio has moved down 2.9 over the prior 243 months.
  • Over the past 243 months, PFE's price/earnings ratio has gone down 17.6.

Below are key valuation metrics over time for PFE.

Stock Date P/S P/B P/E EV/EBIT
PFE 2021-08-31 5.0 3.7 19.5 20.3
PFE 2021-08-30 5.1 3.7 19.8 20.5
PFE 2021-08-27 5.1 3.7 19.8 20.5
PFE 2021-08-26 5.1 3.8 20.1 20.8
PFE 2021-08-25 5.2 3.8 20.1 20.8
PFE 2021-08-24 5.3 3.9 20.5 21.2

PFE Growth Metrics

  • Its year over year revenue growth rate is now at -12.24%.
  • The 5 year revenue growth rate now stands at 5.71%.
  • Its 4 year net income to common stockholders growth rate is now at 107.78%.
Over the past 33 months, PFE's revenue has gone down $1,736,000,000.

The table below shows PFE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 51,637 23,552 13,228
2021-03-31 44,461 15,808 11,091
2020-12-31 41,908 14,403 9,616
2020-09-30 48,648 12,547 8,685
2020-06-30 49,197 14,967 14,171
2020-03-31 50,660 14,023 15,791

PFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PFE has a Quality Grade of B, ranking ahead of 88.31% of graded US stocks.
  • PFE's asset turnover comes in at 0.312 -- ranking 145th of 677 Pharmaceutical Products stocks.
  • ASMB, XBIT, and NERV are the stocks whose asset turnover ratios are most correlated with PFE.

The table below shows PFE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.312 0.704 0.149
2021-04-04 0.265 0.763 0.116
2020-12-31 0.247 0.793 0.099
2020-09-27 0.282 0.799 0.083
2020-06-28 0.288 0.799 0.181
2020-03-29 0.307 0.799 0.200

PFE Price Target

For more insight on analysts targets of PFE, see our PFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.03 Average Broker Recommendation 1.8 (Hold)

PFE Stock Price Chart Interactive Chart >

Price chart for PFE

PFE Price/Volume Stats

Current price $43.94 52-week high $51.86
Prev. close $44.19 52-week low $33.36
Day low $43.81 Volume 16,150,700
Day high $44.41 Avg. volume 30,754,012
50-day MA $45.32 Dividend yield 3.55%
200-day MA $39.45 Market Cap 246.36B

Pfizer Inc. (PFE) Company Bio


Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products. Pfizer was founded under its original name, Charles Pfizer & Company, in 1849 in Brooklyn, New York by Charles Pfizer and Charles Erhart. The company operates research and development facilities in United States and the United Kingdom and employs over 78,000 individuals worldwide. Some of the company’s more recognizable brands include Advil, Celebrex, Chantix, Chapstick, Dimetapp, Lipitor, Robitussin, and Viagra. Albert Bourla serves as Pfizer’s Chairman of the Board and Chief Executive Officer and the company is headquartered in New York, New York.


PFE Latest News Stream


Event/Time News Detail
Loading, please wait...

PFE Latest Social Stream


Loading social stream, please wait...

View Full PFE Social Stream

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Pfizer Nabs Booster OK In U.S. — But How Long Will It Hold The Covid Lead?

Vaccine stocks popped Thursday after the FDA authorized Pfizer and BioNTech's Covid booster shot for at-risk groups.

Yahoo | September 23, 2021

CDC Advisors Recommend Pfizer Booster Shots for Older Americans. What to Know.

An advisory committee to the agency rejected a recommendation for boosters for people aged 18 to 64 in an occupational or institutional setting where the risk of transmission is high.

Yahoo | September 23, 2021

CDC Panel Backs Booster Shots; Federal Workers Sue: Virus Update

(Bloomberg) -- A Centers for Disease Control and Prevention advisory panel backed booster shots of the Pfizer Inc.-BioNTech SE vaccine for people ages 65 and older in the U.S. People over 18 with weakened immune systems were also recommended for an extra dose.Most Read from BloombergSchool Reopenings Falter as U.S. Kids Near 1 Million Covid CasesIstanbul Turns Taps on Old Fountains, Joining Global Push for Free DrinksIn Paris, the Wrapped Arc de Triomphe Is a Polarizing PackageHow the Child Care

Yahoo | September 23, 2021

CDC advisory panel votes to recommend Pfizer/BioNTech boosters for certain segments of population

A CDC advisory panel voted Thursday to recommend COVID-19 boosters of the Pfizer/BioNTech vaccine for a broad population of U.S. residents.

Yahoo | September 23, 2021

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.

Yahoo | September 23, 2021

Read More 'PFE' Stories Here

PFE Price Returns

1-mo -7.26%
3-mo 13.75%
6-mo 22.27%
1-year 33.90%
3-year 18.99%
5-year 66.69%
YTD 22.96%
2020 3.23%
2019 -6.91%
2018 24.82%
2017 15.90%
2016 4.42%

PFE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PFE Dividend History

Continue Researching PFE

Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:

Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9667 seconds.